本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

Sarepta Therapeutics

17.96
+1.7010.46%
盘后17.73-0.2490-1.38%19:59 EDT
成交量:1,657.66万
成交额:2.96亿
市值:17.55亿
市盈率:-29.99
高:19.26
开:18.25
低:17.17
收:16.26
52周最高:145.00
52周最低:10.42
股本:9,771.34万
流通股本:8,828.85万
量比:1.30
换手率:18.78%
股息:- -
股息率:- -
每股收益(TTM):-0.5989
每股收益(LYR):2.47
净资产收益率:-23.61%
总资产收益率:-2.19%
市净率:1.54
市盈率(LYR):7.26

数据加载中...

公司资料

公司名字:
Sarepta Therapeutics
交易所:
NASDAQ
成立时间:
1980
员工人数:
1372
公司地址:
215 First Street,Suite 415,Cambridge,Massachusetts,United States
邮编:
02142
电话:
传真:
- -
简介:
Sarepta Therapeutics, Inc.于1980年7月22日在俄勒冈州注册成立。该公司是一家商业阶段的生物制药公司,专注于通过发现和开发独特的RNA靶向疗法、基因疗法和其他用于治疗罕见疾病的基因治疗模式来帮助患者。应用他们的专有、高度差异化和创新技术,并通过与战略合作伙伴的合作,该公司开发了多个获批产品,用于治疗杜氏肌营养不良症,并正在为广泛的疾病和紊乱开发潜在的候选治疗药物,包括杜氏、肢带型肌营养不良症和其他与神经肌肉和中枢神经系统相关的疾病。

董事

名称
职位
Douglas Ingram
Director,Chief Executive Officer
Claude Nicaise
Independent Director
Deirdre P. Connelly
Independent Director
Hans Wigzell
Independent Director
Kathryn Jean Boor
Independent Director
M. Kathleen Behrens
Chairwoman of the Board
Michael A. Chambers
Independent Director
Richard J. Barry
Independent Director
Stephen L. Mayo
Independent Director

股东

名称
职位
Douglas Ingram
Director,Chief Executive Officer
Ian Estepan
President and Chief Operating Officer
Ryan Wong
Executive Vice President, Chief Financial Officer,Principal Accounting Officer
Bilal Arif
Executive Vice President and Chief Technical Operations Officer
Cristin Rothfuss
Executive Vice President, Chief General Counsel and Corporate Secretary
Louise Rodino Klapac
President, Research and Development and Technical Operations